Search research articles
Contact Us
Filters
Showing results (1-10 of 78) with videos related to
Page
of 8
Sort By:
Bulletin Du Cancer
|
March 8, 2024
[Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer]
Hanna Besnainou, Luc Cabel
Bulletin Du Cancer
|
February 26, 2025
[Benefits and limitations of circulating tumor DNA in breast cancer]
Nicolas Kiavue, Luc Cabel
Cancers
|
March 6, 2021
Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
Florence Lerebours, Luc Cabel, Jean-Yves Pierga
Annals of Translational Medicine
|
August 25, 2021
Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
Daniel V Santi, Luc Cabel, François-Clément Bidard
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2014
Prognosis of t1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas
Luc Cabel, Julien Péron, Paul Henri Cottu, et al.
Journal of the National Cancer Institute
|
October 14, 2022
Invasive Lobular Carcinoma of the Breast: Toward Tailoring Therapy?
Lounes Djerroudi, Luc Cabel, Francois-Clement Bidard, et al.
Bulletin Du Cancer
|
January 11, 2021
[Squamous cell anal carcinoma. What's next ?]
Stefano Kim, Laurie Spehner, Luc Cabel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
January 18, 2024
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
Daniel V Santi, Gary W Ashley, Luc Cabel, et al.
Molecular Oncology
|
December 8, 2020
Clinical utility of circulating tumor cells: an update
Antoine Vasseur, Nicolas Kiavue, François-Clément Bidard, et al.
Journal of Breast Cancer
|
May 13, 2020
<i>ESR1</i> Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
Marcela Carausu, Samia Melaabi, Jean-Yves Pierga, et al.
Page
of 8
Search research articles
Search
Showing results (1-10 of 78) with videos related to
Sort By:
Page
of 8
Bulletin Du Cancer
|
March 8, 2024
[Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer]
Hanna Besnainou, Luc Cabel
Bulletin Du Cancer
|
February 26, 2025
[Benefits and limitations of circulating tumor DNA in breast cancer]
Nicolas Kiavue, Luc Cabel
Cancers
|
March 6, 2021
Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
Florence Lerebours, Luc Cabel, Jean-Yves Pierga
Annals of Translational Medicine
|
August 25, 2021
Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
Daniel V Santi, Luc Cabel, François-Clément Bidard
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2014
Prognosis of t1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas
Luc Cabel, Julien Péron, Paul Henri Cottu, et al.
Journal of the National Cancer Institute
|
October 14, 2022
Invasive Lobular Carcinoma of the Breast: Toward Tailoring Therapy?
Lounes Djerroudi, Luc Cabel, Francois-Clement Bidard, et al.
Bulletin Du Cancer
|
January 11, 2021
[Squamous cell anal carcinoma. What's next ?]
Stefano Kim, Laurie Spehner, Luc Cabel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
January 18, 2024
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
Daniel V Santi, Gary W Ashley, Luc Cabel, et al.
Molecular Oncology
|
December 8, 2020
Clinical utility of circulating tumor cells: an update
Antoine Vasseur, Nicolas Kiavue, François-Clément Bidard, et al.
Journal of Breast Cancer
|
May 13, 2020
<i>ESR1</i> Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
Marcela Carausu, Samia Melaabi, Jean-Yves Pierga, et al.
Page
of 8